Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P05231 (
interleukin-6
)
23,907
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
To test the hypothesis that
interleukin-6
(
IL-6
) contributes to the development of ventilator-associated lung injury (VALI),
IL-6
-deficient (IL6(-/-)) and wild-type control (WT) mice received intratracheal hydrochloric acid followed by randomization to mechanical ventilation (MV + IT HCl) or spontaneous ventilation (IT HCl). After 4 hours, injury was assessed by estimation of lung lavage protein concentration and total and differential cell counts, wet/dry lung weight ratio, pulmonary cell death, histologic inflammation score (
LIS
), and parenchymal myeloperoxidase (MPO) concentration. Vascular endothelial growth factor (VEGF) concentration was measured in lung lavage and homogenate, as
IL-6
and stretch both regulate expression of this potent mediator of permeability. MV-induced increases in alveolar barrier dysfunction and lavage VEGF were attenuated in IL6(-/-) mice as compared with WT controls, whereas tissue VEGF concentration increased. The effects of
IL-6
deletion on alveolar permeability and VEGF concentration were inflammation independent, as parenchymal MPO concentration,
LIS
, and lavage total and differential cell counts did not differ between WT and IL6(-/-) mice following MV + IT HCl. These data support a role for
IL-6
in promoting VALI in this two-hit model. Strategies to interfere with
IL-6
expression or signaling may represent important therapeutic targets to limit the injurious effects of MV in inflamed lungs.
...
PMID:Interleukin-6 mediates pulmonary vascular permeability in a two-hit model of ventilator-associated lung injury. 2204 13